All reagents were used without further purification and bought from common commercial suppliers. Proton (¹H) and carbon (¹³C) NMR spectra (400 or 300 MHz for ¹HNMR; 101 or 75 MHz for ¹³CNMR) were recorded on a Bruker spectrometer (Bruker Company, Germany). NMR spectra used DMSO-d ₆ , MeOD, or CDCl₃ as a solvent. Proton chemical shifts are reported relative to a residual solvent peak (CDCl₃ at 7.26 ppm, DMSO-d ₆ at 2.50 ppm, MeOD at 3.31 ppm). Carbon chemical shifts are reported relative to a residual solvent peak (CDCl₃ at 77.00 ppm, DMSO-d ₆ at 39.60 ppm, MeOD at 49.00 ppm). The values of the chemical shifts are expressed in ppm and the coupling constants (J) in hertz. The following abbreviations were used to designate multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. High-resolution mass spectrometry (HRMS) was obtained on an Agilent UPLC-IM-QTOF spectrometer (Agilent 6560, United States). Mass spectrometry (MS) analysis was performed using a liquid chromatograph-mass spectrometer (LC-MS). The purity was determined by high-performance liquid chromatography (HPLC). The purity of all final compounds was more than 95% (Agilent 1260 Infinity II; United States). The column was Eclipse Plus C18 (4.6 × 150 mm, 4 µm). Chromatographic conditions for all compounds: Mobile phase: 0–7 min, MeOH:H₂O = 20:80; 7–16 min MeOH:H₂O = 95:5, 16–25 min MeOH:H₂O = 20:80; wavelength: 254 nm; column temperature: 25°C; flow rate of 0.5 ml/min. All synthesized compounds are >95% pure by HPLC analysis.

2a : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl propylcarbamate: white solid (68% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.88 (s, 1H, NH), 7.25 (d, J = 7.6 Hz, 4H, aromatic protons), 7.20 – 7.14 (m, 4H, aromatic protons), 7.09 (m, 3H, aromatic protons), 6.97 – 6.90 (m, 2H, aromatic protons), 6.72 (m, 1H, aromatic proton), 6.57 (s, 1H, CH), 3.53 (s, 4H, CH₂), 3.11 (q, J = 6.7 Hz, 2H, CH₂), 2.74 (m, 2H, CH₂), 2.61 (m, 2H, CH₂), 1.46 (m, 2H, CH₂), 0.84 (t, J = 7.4 Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ 156.15, 144.36, 140.14, 134.15, 129.09, 128.45, 128.04, 127.05, 123.16, 116.37, 111.63, 111.28, 58.53, 54.01, 43.28, 23.43, 23.18, 11.57. MS (ESI⁺) m/z calcd for C₂₈H₃₂N₃O₂ ⁺ [M+H]⁺ 442.2, found 442.2. Purity = 96.4%.

2b : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl butylcarbamate: orange solid (70% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.89 (s, 1H, NH), 7.36 – 7.30 (m, 4H, aromatic protons), 7.27 – 7.21 (m, 4H, aromatic protons), 7.18 (m, 1H, aromatic proton), 7.16 (d, J = 2.3 Hz, 1H, aromatic proton), 7.15 – 7.10 (m, 1H, aromatic proton), 7.02 (d, J = 2.3 Hz, 1H, aromatic proton), 6.83 (m, 1H, aromatic proton), 6.75 (d, J = 2.3 Hz, 1H, CH), 3.61 (s, 4H, CH₂), 3.23 (q, J = 6.7 Hz, 2H, CH₂), 2.84 (m, 2H, CH₂), 2.73 – 2.67 (m, 2H, CH₂), 1.56 – 1.46 (m, 2H, CH₂), 1.41 – 1.29 (m, 2H, CH₂), 0.91 (t, J = 7.3 Hz, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.73, 144.26, 139.90, 133.89, 128.94, 128.83, 128.24, 128.19, 127.88, 126.79, 122.77, 116.30, 114.73, 111.27, 111.15, 58.31, 53.76, 41.04, 32.04, 22.97, 19.98, 13.80. MS (ESI⁺) m/z calcd for C₂₉H₃₄N₃O₂ ⁺ [M+H]⁺ 456.3, found 456.3. Purity = 96.2%.

2c : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl pentylcarbamate: orange solid (63% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.99 (s, 1H, NH), 7.36 (d, J = 7.1 Hz, 4H, aromatic protons), 7.28 (t, J = 7.4 Hz, 4H, aromatic protons), 7.22 (s, 1H, aromatic proton), 7.20 (d, J = 7.2 Hz, 2H, aromatic protons), 7.08 (d, J = 8.7 Hz, 1H, aromatic proton), 7.05 (d, J = 2.1 Hz, 1H, aromatic proton), 6.84 (m, 1H, aromatic proton), 6.69 (s, 1H, CH), 3.65 (s, 4H, CH₂), 3.25 (q, J = 6.8 Hz, 2H, CH₂), 2.89 – 2.82 (m, 2H, CH₂), 2.72 (m, 2H, CH₂), 1.57 (q, J = 7.0 Hz, 2H, CH₂), 1.34 (m, 4H, CH₂), 0.91 (t, J = 6.7 Hz, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.82, 144.13, 139.87, 133.88, 128.90, 128.81, 128.21, 128.17, 127.78, 126.76, 122.85, 116.13, 114.41, 111.33, 111.02, 58.26, 53.74, 41.30, 29.59, 28.93, 22.90, 22.36, 14.02. MS (ESI⁺) m/z calcd for C₃₀H₃₆N₃O₂ ⁺ [M+H]⁺ 470.3, found 470.3. Purity = 97.9%.

2d : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl hexylcarbamate: brown solid (67% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.93 (s, 1H, NH), 7.28 (s, 2H, aromatic protons), 7.19 (t, J = 7.4 Hz, 4H, aromatic protons), 7.11 (m, 3H, aromatic protons), 7.00 – 6.93 (m, 2H, aromatic protons), 6.74 (m, 1H, aromatic proton), 6.58 (s, 1H, CH), 3.55 (s, 4H, CH₂), 3.16 (q, J = 6.8 Hz, 2H, CH₂), 2.76 (m, 2H, CH₂), 2.63 (m, 2H, CH₂), 1.46 (t, J = 7.3 Hz, 2H, CH₂), 1.29 – 1.17 (m, 6H, CH₂), 0.83 – 0.77 (m, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.83, 144.11, 139.84, 133.88, 128.90, 128.81, 128.17, 127.77, 126.77, 122.87, 116.10, 114.35, 111.34, 111.00, 58.25, 53.73, 41.33, 31.47, 29.86, 26.45, 22.88, 22.57, 14.04. MS (ESI⁺) m/z calcd for C₃₁H₃₈N₃O₂ ⁺ [M+H]⁺ 484.3, found 484.3. Purity = 95.4%.

2e : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl heptylcarbamate: white solid (65% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 7.87 (s, 1H, NH), 7.29 (d, J = 2.1 Hz, 2H, aromatic protons), 7.19 (t, J = 7.3 Hz, 5H, aromatic protons), 7.12 (m, 2H, aromatic protons), 7.03 (d, J = 8.5 Hz, 1H, aromatic proton), 6.96 (d, J = 2.4 Hz, 1H, aromatic proton), 6.76 (m, 1H, aromatic proton), 6.65 (d, J = 2.3 Hz, 1H, CH), 3.56 (s, 4H, CH₂), 3.17 (q, J = 6.7 Hz, 2H, CH₂), 2.77 (m, 2H, CH₂), 2.64 (m, 2H, CH₂), 1.47 (d, J = 8.7 Hz, 2H, CH₂), 1.34 – 1.11 (m, 8H, CH₂), 0.87 – 0.72 (m, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.78, 144.19, 139.89, 133.89, 128.92, 128.82, 128.23, 128.18, 126.78, 122.82, 116.21, 114.56, 111.31, 111.08, 58.39, 58.29, 53.75, 41.35, 31.78, 29.93, 28.98, 26.77, 22.94, 22.62, 14.11. MS (ESI⁺) m/z calcd for C₃₂H₄₀N₃O₂ ⁺ [M+H]⁺ 498.3, found 498.3. Purity = 96.4%.

2f : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl cyclopropylcarbamate: white solid (70% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.97 (s, 1H, NH), 7.39 – 7.34 (m, 4H, aromatic protons), 7.32 – 7.25 (m, 4H, aromatic protons), 7.25 – 7.22 (m, 1H, aromatic proton), 7.22 – 7.17 (m, 2H, aromatic protons), 7.13 (d, J = 8.7 Hz, 1H, aromatic proton), 7.06 (d, J = 2.2 Hz, 1H, aromatic proton), 6.88 – 6.82 (m, 1H, aromatic proton), 6.75 (d, J = 2.3 Hz, 1H, CH), 3.66 (s, 4H, CH₂), 2.87 (m, 2H, CH₂), 2.79 – 2.66 (m, 3H, CH₂, CH), 0.85 – 0.71 (m, 2H, CH₂), 0.69 – 0.53 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 156.38, 144.12, 139.93, 133.94, 128.84, 128.21, 127.85, 126.87, 126.80, 122.87, 116.17, 114.61, 111.33, 111.08, 58.32, 53.79, 23.37, 22.98, 6.93. MS (ESI⁺) m/z calcd for C₂₈H₃₀N₃O₂ ⁺ [M+H]⁺ 440.2, found 440.2. Purity = 97.4%.

2g : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl cyclopentylcarbamate: white solid (69% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 7.93 (s, 1H, NH), 7.34 (d, J = 7.1 Hz, 4H, aromatic protons), 7.26 (t, J = 7.3 Hz, 4H, aromatic protons), 7.19 (d, J = 6.7 Hz, 2H, aromatic protons), 7.10 (d, J = 8.5 Hz, 1H, aromatic proton), 7.03 (d, J = 2.2 Hz, 1H, aromatic proton), 6.87 – 6.79 (m, 1H, aromatic proton), 6.73 (s, 1H, CH), 4.94 (d, J = 7.3 Hz, 1H, CH), 3.63 (s, 4H, CH₂), 2.91 – 2.79 (m, 2H, CH₂), 2.71 (m, 2H, CH₂), 2.07 – 1.93 (m, 2H, CH₂), 1.76 – 1.55 (m, 4H, CH₂), 1.47 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 144.39, 140.11, 134.10, 129.05, 128.41, 128.06, 127.01, 123.01, 116.49, 114.80, 111.51, 111.34, 58.51, 53.97, 53.24, 33.51, 23.82, 23.17. MS (ESI⁺) m/z calcd for C₃₀H₃₄N₃O₂ ⁺ [M+H]⁺ 468.3, found 468.3. Purity = 96.4%.

2h : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl cyclohexylcarbamate: bright solid (61% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 8.05 (s, 1H, NH), 7.43 (d, J = 6.5 Hz, 4H, aromatic protons), 7.35 (t, J = 7.4 Hz, 4H, aromatic protons), 7.27 (m, 2H, aromatic protons), 7.15 – 7.08 (m, 2H, aromatic protons), 6.90 (m, 1H, aromatic proton), 6.75 (m, 1H, CH), 5.00 (d, J = 8.1 Hz, 1H, CH), 3.71 (s, 4H, CH₂), 2.91 (m, 2H, CH₂), 2.78 (m, 2H, CH₂), 2.07 (d, J = 10.8 Hz, 2H, CH₂), 1.72 (m, 3H, CH₂, CH), 1.50 – 1.35 (m, 2H, CH₂), 1.26 (q, J = 11.6 Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ 154.95, 144.05, 139.85, 133.83, 128.88, 128.79, 128.16, 127.73, 126.75, 122.82, 116.13, 114.32, 111.31, 111.01, 58.31, 58.22, 53.70, 50.08, 33.32, 25.46, 24.78, 22.87. MS (ESI⁺) m/z calcd for C₃₁H₃₆N₃O₂ ⁺ [M+H]⁺ 482.3, found 482.3. Purity = 96.1%.

2i : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl phenylcarbamate: orange solid (66% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.95 (s, 1H, NH), 7.44 (d, J = 8.0 Hz, 2H, aromatic protons), 7.35 (d, J = 7.5 Hz, 4H, aromatic protons), 7.30 (s, 1H, aromatic proton), 7.25 (d, J = 7.4 Hz, 3H, aromatic protons), 7.18 (q, J = 8.3, 6.7 Hz, 3H, aromatic protons), 7.13 – 7.08 (m, 1H, aromatic proton), 7.07 – 7.04 (m, 2H, aromatic protons), 7.03 – 7.00 (m, 1H, aromatic proton), 6.89 (m, 1H, aromatic proton), 6.76 (s, 1H, CH), 3.64 (s, 4H, CH₂), 2.86 (m, 2H, CH₂), 2.73 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 143.60, 139.79, 137.66, 134.01, 129.10, 128.76, 128.14, 127.81, 126.75, 123.67, 122.93, 118.63, 115.99, 114.60, 111.36, 111.15, 58.25, 53.62, 22.90. MS (ESI⁺) m/z calcd for C₃₁H₃₀N₃O₂ ⁺ [M+H]⁺ 476.2, found 476.2. Purity = 95.2%.

2j : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl dimethylcarbamate: white solid (64% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.91 (s, 1H, NH), 7.42 – 7.36 (m, 4H, aromatic protons), 7.30 (t, J = 7.5 Hz, 4H, aromatic protons), 7.25 – 7.19 (m, 3H, aromatic protons), 7.06 (d, J = 2.2 Hz, 1H, aromatic proton), 6.89 (m, 1H, aromatic proton), 6.85 (d, J = 2.3 Hz, 1H, CH), 3.68 (s, 4H, CH₂), 3.15 (s, 3H, CH₃), 3.05 (s, 3H, CH₃), 2.91 (m, 2H, CH₂), 2.78 (m, 2H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 156.44, 144.81, 140.20, 134.13, 129.08, 128.44, 128.03, 127.01, 123.09, 116.49, 114.57, 111.57, 111.32, 58.60, 58.51, 54.02, 37.02, 36.74, 23.20. MS (ESI⁺) m/z calcd for C₂₇H₃₀N₃O₂ ⁺ [M+H]⁺ 428.2, found 428.2. Purity = 95.8%.

2k : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl diethylcarbamate: orange solid (66% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 8.03 (s, 1H, NH), 7.40 (d, J = 7.1 Hz, 4H, aromatic protons), 7.32 (t, J = 7.3 Hz, 4H, aromatic protons), 7.27 – 7.21 (m, 2H, aromatic protons), 7.14 (d, J = 8.7 Hz, 1H, aromatic proton), 7.08 (d, J = 2.2 Hz, 1H, aromatic proton), 6.87 (m, 1H, aromatic proton), 6.75 (d, J = 2.2 Hz, 1H, CH), 3.69 (s, 4H, CH₂), 3.48 (q, J = 8.0 Hz, 4H, CH₂), 2.91 (m, 2H, CH₂), 2.77 (m, 2H, CH₂), 1.35 – 1.22 (m, 6H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ 155.34, 144.54, 139.83, 133.75, 128.76, 128.11, 127.75, 126.71, 122.64, 116.30, 114.36, 111.16, 111.01, 58.18, 53.66, 41.80, 22.84, 14.28, 13.42. MS (ESI⁺) m/z calcd for C₂₉H₃₄N₃O₂ ⁺ [M+H]⁺ 456.3, found 456.3. Purity = 95.5%.

2l : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl dipropylcarbamate: orange solid (61% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 9.39 (s, 1H, NH), 8.74 (t, J = 5.0 Hz, 4H, aromatic protons), 8.66 (m, 4H, aromatic protons), 8.58 (m, 2H, aromatic protons), 8.44 (m, 2H, aromatic protons), 8.19 (q, J = 3.6 Hz, 1H, aromatic proton), 8.06 (s, 1H, CH), 5.03 (d, J = 3.7 Hz, 4H, CH₂), 4.70 (m, 4H, CH₂), 4.32 – 4.18 (m, 2H, CH₂), 4.11 (m, 2H, CH₂), 3.06 (s, 4H, CH₂), 2.35 (m, 6H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.94, 144.67, 139.97, 133.85, 128.95, 128.85, 128.21, 127.83, 126.79, 122.75, 116.32, 114.42, 111.27, 111.02, 58.29, 53.80, 49.58, 49.27, 22.93, 22.13, 21.39, 11.40. MS (ESI⁺) m/z calcd for C₃₁H₃₈N₃O₂ ⁺ [M+H]⁺ 484.3, found 484.3. Purity = 96.5%.

2m : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl dibutylcarbamate: orange solid (60% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 9.27 (s, 1H, NH), 8.67 (d, J = 7.3 Hz, 4H, aromatic protons), 8.58 (t, J = 7.3 Hz, 4H, aromatic protons), 8.51 (d, J = 7.5 Hz, 2H, aromatic protons), 8.43 (d, J = 8.7 Hz, 1H, aromatic proton), 8.35 (d, J = 2.3 Hz, 1H, aromatic proton), 8.13 (d, J = 8.6 Hz, 1H, aromatic proton), 8.03 (s, 1H, CH), 4.96 (m, 4H, CH₂), 4.67 (m, 4H, CH₂), 4.17 (d, J = 7.9 Hz, 2H, CH₂), 4.10 – 3.98 (m, 2H, CH₂), 2.94 (m, 4H, CH₂), 2.69 (q, J = 9.8, 8.3 Hz, 4H, CH₂), 2.26 (q, J = 7.3 Hz, 6H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.80, 144.73, 139.94, 133.81, 128.83, 128.19, 127.86, 126.77, 122.66, 116.38, 114.55, 111.20, 111.07, 58.28, 53.78, 47.57, 47.23, 31.04, 30.28, 22.93, 20.14, 13.96. MS (ESI⁺) m/z calcd for C₃₃H₄₂N₃O₂ ⁺ [M+H]⁺ 512.3, found 512.3. Purity = 98.1%.

2n: 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl diphenylcarbamate: orange solid (67% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 7.90 (s, 1H, NH), 7.41 – 7.32 (m, 12H, aromatic protons), 7.29 (d, J = 1.3 Hz, 1H, aromatic proton), 7.28 – 7.23 (m, 4H, aromatic protons), 7.23 – 7.15 (m, 3H, aromatic protons), 7.12 (d, J = 8.6 Hz, 1H, aromatic proton), 7.09 (d, J = 2.3 Hz, 1H, aromatic proton), 6.88 (m, 1H, aromatic proton), 6.73 (d, J = 2.3 Hz, 1H, CH), 3.65 (s, 4H, CH₂), 2.87 (m, 2H, CH₂), 2.73 (m, 2H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 154.09, 144.23, 142.53, 139.82, 133.84, 128.95, 128.74, 128.12, 127.71, 126.91, 126.73, 126.23, 122.74, 115.87, 114.58, 111.16, 110.87, 58.21, 53.63, 22.88. MS (ESI⁺) m/z calcd for C₃₇H₃₄N₃O₂ ⁺ [M+H]⁺ 552.3, found 552.3. Purity = 98.9%.

2o : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl methoxy(methyl)carbamate: brown solid (65% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 7.96 (s, 1H, NH), 7.38 (d, J = 7.4 Hz, 4H, aromatic protons), 7.29 (m, 4H, aromatic protons), 7.25 – 7.16 (m, 3H, aromatic protons), 7.09 (s, 1H, aromatic proton), 6.90 (d, J = 8.3 Hz, 1H, aromatic proton), 6.82 (s, 1H, CH), 3.84 (d, J = 2.4 Hz, 3H, CH₃), 3.68 (s, 4H, CH₂), 3.33 (d, J = 2.4 Hz, 3H, CH₃), 2.95 – 2.85 (m, 2H, CH₂), 2.77 (d, J = 7.9 Hz, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 156.32, 144.08, 139.83, 133.98, 128.79, 128.15, 127.82, 126.76, 122.86, 115.99, 114.69, 111.28, 111.03, 61.78, 58.26, 53.68, 35.77, 22.93. HRMS (ESI⁺) m/z calcd for C₂₇H₃₀N₃O₃ ⁺ [M+H]⁺ 444.2282, found 444.2307. Purity = 96.7%.

2p : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl methyl(phenyl)carbamate: orange solid (70% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.91 (s, 1H, NH), 7.42 (d, J = 4.3 Hz, 4H, aromatic protons), 7.38 (d, J = 7.5 Hz, 4H, aromatic protons), 7.29 (t, J = 7.4 Hz, 5H, aromatic protons), 7.21 (m, 3H, aromatic protons), 7.07 (s, 1H, aromatic proton), 6.89 (d, J = 8.7 Hz, 1H, aromatic proton), 6.84 (s, 1H, CH), 3.68 (s, 4H, CH₂), 3.48 (m, 3H, CH₃), 2.91 (m, 2H, CH₂), 2.77 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 154.97, 144.54, 143.25, 133.85, 128.94, 128.82, 128.16, 127.80, 126.79, 125.78, 122.69, 116.22, 111.13, 111.06, 58.23, 53.63, 38.13, 22.89. HRMS (ESI⁺) m/z calcd for C₃₂H₃₂N₃O₂ ⁺ [M+H]⁺ 490.2489, found 490.2508. Purity = 96.9%.

2q : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl azetidine-1-carboxylate: brown solid (50% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.96 (s, 1H, NH), 7.37 (d, J = 7.0 Hz, 4H, aromatic protons), 7.29 (t, J = 7.5 Hz, 4H, aromatic protons), 7.24 – 7.19 (m, 2H, aromatic protons), 7.14 (m, 1H, aromatic proton), 7.06 (d, J = 2.3 Hz, 1H, aromatic proton), 6.86 (m, 1H, aromatic proton), 6.77 (d, J = 2.7 Hz, 1H, CH), 4.35 – 4.03 (m, 4H, CH₂), 3.66 (s, 4H, CH₂), 2.88 (m, 2H, CH₂), 2.79 – 2.71 (m, 2H, CH₂), 2.40 – 2.27 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 155.53, 144.15, 139.86, 133.83, 128.78, 128.13, 127.80, 126.71, 122.70, 116.19, 114.52, 111.19, 111.02, 58.22, 53.74, 22.92, 15.79. HRMS (ESI⁺) m/z calcd for C₂₈H₃₀N₃O₂ ⁺ [M+H]⁺ 440.2333, found 440.2332. Purity = 95.3%.

2r : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl pyrrolidine-1-carboxylate: brown solid (53% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 7.96 (s, 1H, NH), 7.42 – 7.34 (m, 4H, aromatic protons), 7.33 – 7.26 (m, 4H, aromatic protons), 7.23 (m, 1H, aromatic proton), 7.20 (d, J = 2.7 Hz, 1H, aromatic proton), 7.18 – 7.12 (m, 1H, aromatic proton), 7.07 (d, J = 2.2 Hz, 1H, aromatic proton), 6.88 (m, 1H, aromatic proton), 6.77 (d, J = 2.3 Hz, 1H, CH), 3.66 (s, 4H, CH₂), 3.60 (t, J = 6.5 Hz, 2H, CH₂), 3.51 (t, J = 6.5 Hz, 2H, CH₂), 2.89 (dd, J = 9.4, 5.8 Hz, 2H, CH₂), 2.81 – 2.70 (m, 2H, CH₂), 2.05 – 1.87 (m, 4H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 154.32, 144.49, 139.86, 133.77, 128.76, 128.11, 127.78, 126.68, 122.61, 116.39, 114.50, 111.13, 58.19, 53.71, 46.41, 46.30, 25.87, 25.03, 22.91. MS (ESI⁺) m/z calcd for C₂₉H₃₂N₃O₂ ⁺ [M+H]⁺ 454.2, found 454.2. Purity = 96.0%.

2s : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl piperidine-1-carboxylate: brown solid (57% yield). ¹H NMR (300 MHz, CDCl₃-d) δ 8.02 (s, 1H, NH), 7.37 (d, J = 7.1 Hz, 4H, aromatic protons), 7.33 – 7.25 (m, 4H, aromatic protons), 7.20 (m, J = 6.1, 1.7 Hz, 2H, aromatic protons), 7.08 (d, J = 8.8 Hz, 1H, aromatic proton), 7.03 (d, J = 2.3 Hz, 1H, aromatic proton), 6.83 (dd, J = 8.6, 2.3 Hz, 1H, aromatic proton), 6.68 (d, J = 2.3 Hz, 1H, CH), 3.65 (s, 6H, CH₂), 3.55 (s, 2H, CH₂), 2.86 (dd, J = 9.6, 5.7 Hz, 2H, CH₂), 2.72 (dd, J = 10.2, 5.9 Hz, 2H, CH₂), 1.65 (s, 6H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 154.91, 144.50, 139.79, 133.75, 128.75, 128.11, 127.70, 126.70, 122.69, 116.21, 114.22, 111.20, 110.97, 58.14, 53.65, 45.34, 45.02, 25.86, 25.58, 24.34, 22.82. MS (ESI⁺) m/z calcd for C₃₀H₃₄N₃O₂ ⁺ [M+H]⁺ 468.3, found 468.3. Purity = 96.1%.

2t : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl azepane-1-carboxylate: orange solid (58% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.97 – 7.90 (m, 1H, NH), 7.32 (d, J = 7.1 Hz, 4H, aromatic protons), 7.24 (m, 4H, aromatic protons), 7.18 (t, J = 1.8 Hz, 1H, aromatic protons), 7.16 – 7.13 (m, 1H, aromatic protons), 7.07 (d, J = 8.7 Hz, 1H, aromatic proton), 7.01 (d, J = 2.2 Hz, 1H, aromatic protons), 6.80 (dd, J = 8.7, 2.3 Hz, 1H, aromatic protons), 6.68 (d, J = 2.3 Hz, 1H, CH), 3.61 (s, 4H, CH₂), 3.59 – 3.54 (m, 2H, CH₂), 3.50 (t, J = 6.1 Hz, 2H, CH₂), 2.83 (m, 2H, CH₂), 2.70 (m, 2H, CH₂), 1.84 – 1.68 (m, 4H, CH₂), 1.60 (m, 4H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 155.82, 144.72, 139.94, 133.84, 128.84, 128.19, 127.86, 126.78, 122.70, 116.42, 114.51, 111.24, 111.09, 58.28, 53.79, 47.39, 47.15, 28.82, 28.24, 27.59, 27.03, 22.95. MS (ESI⁺) m/z calcd for C₃₁H₃₆N₃O₂ ⁺ [M+H]⁺ 482.3, found 482.3. Purity = 96.3%.

2u : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl morpholine-4-carboxylate: white solid (59% yield). ¹H NMR (400 MHz, CDCl₃-d) δ 7.98 (s, 1H, NH), 7.36 (d, J = 7.0 Hz, 4H, aromatic protons), 7.28 (t, J = 7.5 Hz, 4H, aromatic protons), 7.22 (m, 1H, aromatic proton), 7.21 – 7.18 (m, 1H, aromatic proton), 7.16 – 7.11 (m, 2H, aromatic proton), 7.05 (d, J = 2.3 Hz, 1H, aromatic proton), 6.85 (dd, J = 8.7, 2.3 Hz, 1H, aromatic proton), 6.73 (d, J = 2.2 Hz, 1H, CH), 3.76 (m, 4H, CH₂), 3.72 – 3.54 (m, 8H, CH₂), 2.87 (m, 2H, CH₂), 2.74 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 154.95, 144.37, 139.91, 133.97, 128.85, 128.57, 128.22, 127.90, 126.80, 122.94, 116.14, 114.57, 111.37, 111.08, 66.73, 58.29, 53.79, 44.88, 44.23, 22.98. MS (ESI⁺) m/z calcd for C₂₉H₃₀N₃O₃ ⁺ [M+H]⁺ 470.2, found 470.2. Purity = 95.3%.

3a: 3-(2-(benzylamino)ethyl)-1H-indol-5-yl propylcarbamate: white solid (85% yield). ¹H NMR (400 MHz, MeOD) δ 7.42 – 7.34 (m, 5H, aromatic protons), 7.32 (d, J = 8.7 Hz, 1H, NH), 7.25 (d, J = 2.2 Hz, 1H, aromatic proton), 7.14 (s, 1H, aromatic proton), 6.86 (dd, J = 8.7, 2.3 Hz, 1H, CH), 4.00 (s, 2H, CH₂), 3.15 (t, J = 7.1 Hz, 2H, CH₂), 3.11 (m, 2H, CH₂), 3.07 – 3.00 (m, 2H, CH₂), 1.59 (m, 2H, CH₂), 0.97 (t, J = 7.4 Hz, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 158.31, 145.49, 135.63, 135.02, 130.27, 129.78, 129.59, 128.24, 125.29, 117.05, 112.55, 111.37, 52.67, 49.06, 43.60, 23.90, 23.85, 11.42. MS (ESI⁺) m/z calcd for C₂₁H₂₆N₃O₂ ⁺ [M+H]⁺ 352.2, found 352.2. Purity = 95.1%.

3b : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl butylcarbamate: white solid (88% yield). ¹H NMR (400 MHz, MeOD) δ 7.46 (m, J = 10.9, 3.9, 2.1 Hz, 5H, aromatic protons), 7.34 (d, J = 8.7 Hz, 1H, NH), 7.27 (d, J = 2.2 Hz, 1H, aromatic proton), 7.21 (s, 1H, aromatic proton), 6.87 (dd, J = 8.7, 2.2 Hz, 1H, CH), 4.16 (s, 2H, CH₂), 3.27 (t, J = 7.7 Hz, 2H, CH₂), 3.20 (t, J = 7.0 Hz, 2H, CH₂), 3.15 – 3.08 (m, 2H, CH₂), 1.61 – 1.50 (m, 2H, CH₂), 1.42 (m, 2H, CH₂), 0.97 (t, J = 7.3 Hz, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 158.28, 145.59, 135.66, 132.47, 130.79, 130.41, 130.05, 128.08, 125.58, 117.20, 112.67, 111.32, 110.30, 52.04, 48.62, 41.54, 32.81, 22.99, 20.79, 13.93. MS (ESI⁺) m/z calcd for C₂₂H₂₈N₃O₂ ⁺ [M+H]⁺ 366.2, found 366.2. Purity = 95.7%.

3c : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl pentylcarbamate: white solid (90% yield). ¹H NMR (400 MHz, MeOD) δ 7.50 (m, J = 7.2, 3.6 Hz, 5H, aromatic protons), 7.38 (d, J = 8.6 Hz, 1H, NH), 7.30 (d, J = 2.3 Hz, 1H, aromatic proton), 7.24 (s, 1H, aromatic proton), 6.91 (dd, J = 8.7, 2.3 Hz, 1H, CH), 4.21 (s, 2H, CH₂), 3.34 (s, 2H, CH₂), 3.22 (t, J = 7.1 Hz, 2H, CH₂), 3.16 (t, J = 7.7 Hz, 2H, CH₂), 1.61 (t, J = 7.1 Hz, 2H, CH ₂), 1.52 – 1.32 (m, 4H, CH₂), 0.98 (t, J = 6.5 Hz, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 158.27, 145.61, 135.67, 132.38, 130.79, 130.45, 130.07, 128.08, 125.59, 117.21, 112.67, 111.31, 110.27, 52.03, 49.23, 41.84, 30.37, 29.92, 23.24, 22.97, 14.17. MS (ESI⁺) m/z calcd for C₂₃H₃₀N₃O₂ ⁺ [M+H]⁺ 380.2, found 380.2. Purity = 95.6%.

3d : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl hexylcarbamate: white solid (93% yield). ¹H NMR (300 MHz, MeOD) δ 7.35 – 7.19 (m, 7H, aromatic protons), 7.06 (s, 1H, NH), 6.84 (dd, J = 8.8, 2.2 Hz, 1H, CH), 3.77 (s, 2H, CH₂), 3.18 (t, J = 7.0 Hz, 2H, CH₂), 2.91 (q, J = 4.4 Hz, 4H, CH₂), 1.63 – 1.49 (m, 2H, CH₂), 1.37 (m, 6H, CH₂), 0.92 (t, J = 6.5 Hz, 3H, CH₃). ¹³C NMR (75 MHz, CD₃OD) δ 157.30, 144.36, 138.41, 134.62, 128.49, 128.38, 127.57, 127.27, 123.84, 115.87, 112.21, 111.37, 110.52, 52.84, 48.89, 40.89, 31.55, 29.70, 26.44, 24.52, 22.52, 13.27. MS (ESI⁺) m/z calcd for C₂₄H₃₂N₃O₂ ⁺ [M+H]⁺ 394.2, found 394.2. Purity = 98.8%.

3e : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl heptylcarbamate: white solid (95% yield). ¹H NMR (400 MHz, MeOD) δ 7.47 (m, J = 6.9, 2.8 Hz, 6H, aromatic protons), 7.35 (d, J = 8.7 Hz, 1H, NH), 7.27 (d, J = 2.2 Hz, 1H, aromatic proton), 7.22 (s, 1H, aromatic proton), 6.87 (dd, J = 8.7, 2.3 Hz, 1H, CH), 4.19 (d, J = 3.4 Hz, 2H, CH₂), 3.28 (d, J = 7.8 Hz, 2H, CH₂), 3.19 (t, J = 7.1 Hz, 2H, CH₂), 3.13 (t, J = 8.0 Hz, 2H, CH₂), 1.57 (t, J = 7.1 Hz, 2H, CH₂), 1.46 – 1.28 (m, 8H, CH₂), 0.96 – 0.88 (m, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 158.27, 145.61, 135.68, 132.34, 130.80, 130.47, 130.08, 128.07, 125.59, 117.21, 112.67, 111.31, 110.24, 52.03, 49.23, 41.87, 32.77, 30.69, 29.94, 27.69, 23.48, 22.97, 14.22. HRMS (ESI⁺) m/z calcd for C₂₅H₃₄N₃O₂ ⁺ [M+H]⁺ 408.2646, found 408.2642. Purity = 98.0%.

3f : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl cyclopropylcarbamate: white solid (88% yield). ¹H NMR (400 MHz, MeOD) δ 7.38 (d, J = 3.3 Hz, 6H, aromatic protons), 7.32 (d, J = 8.7 Hz, 1H, NH), 7.25 (d, J = 2.2 Hz, 1H, aromatic proton), 7.13 (s, 1H, aromatic proton), 6.85 (dd, J = 8.7, 2.2 Hz, 1H, CH), 3.98 (s, 2H, CH₂), 3.09 (m, 2H, CH₂), 3.01 (m, 2H, CH₂), 2.62 (t, J = 3.7 Hz, 1H, CH), 0.71 (m, 2H, CH₂), 0.59 (q, J = 3.7 Hz, 2H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 159.08, 145.37, 135.62, 134.85, 130.29, 129.77, 129.60, 128.22, 125.34, 117.01, 112.58, 111.38, 111.33, 52.60, 49.44, 23.82, 6.50. MS (ESI⁺) m/z calcd for C₂₁H₂₄N₃O₂ ⁺ [M+H]⁺ 350.2, found 350.2. Purity = 97.0%.

3g : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl cyclopentylcarbamate: white solid (89% yield). ¹H NMR (400 MHz, MeOD) δ 7.50 – 7.42 (m, 5H, aromatic protons), 7.34 (d, J = 8.7 Hz, 1H, NH), 7.27 (d, J = 2.2 Hz, 1H, aromatic proton), 7.21 (s, 1H, aromatic proton), 6.87 (dd, J = 8.7, 2.2 Hz, 1H, CH), 4.18 (s, 2H, CH₂), 4.04 – 3.91 (m, 1H, CH), 3.30 – 3.25 (m, 2H, CH₂), 3.17 – 3.08 (m, 2H, CH₂), 1.95 (m, 2H, CH₂), 1.76 (m, 2H, CH₂), 1.59 (m, 4H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 156.58, 144.40, 134.48, 131.18, 129.61, 129.27, 128.89, 126.88, 124.38, 116.05, 111.47, 110.15, 109.07, 52.76, 50.84, 32.28, 23.24, 21.79. HRMS (ESI⁺) m/z calcd for C₂₃H₂₈N₃O₂ ⁺ [M + H]⁺ 378.2176, found 378.2189. Purity = 97.6%.

3h : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl cyclohexylcarbamate: white solid (86% yield). ¹H NMR (400 MHz, MeOD) δ 7.50 – 7.40 (m, 5H, aromatic protons), 7.34 (d, J = 8.7 Hz, 1H, NH), 7.27 (d, J = 2.2 Hz, 1H, aromatic proton), 7.19 (s, 1H, aromatic proton), 6.87 (dd, J = 8.7, 2.3 Hz, 1H, CH), 4.14 (s, 2H, CH₂), 3.45 (m, 1H, CH), 3.24 (m, 2H, CH₂), 3.15 – 3.05 (m, 2H, CH₂), 2.01 – 1.89 (m, 2H, CH₂), 1.78 (m, 2H, CH₂), 1.70 – 1.58 (m, 1H, CH₂), 1.42 – 1.16 (m, 5H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 157.44, 145.56, 135.62, 132.50, 130.77, 130.36, 130.02, 128.08, 125.56, 117.22, 112.65, 111.36, 110.33, 52.03, 51.43, 33.87, 26.40, 25.98, 22.99. MS (ESI⁺) m/z calcd for C₂₄H₃₀N₃O₂ ⁺ [M+H]⁺ 392.2, found 392.2. Purity = 96.0%.

3i : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl phenylcarbamate: white solid (93% yield). ¹H NMR (400 MHz, MeOD) δ 7.55 – 7.49 (m, 2H, aromatic protons), 7.47 – 7.36 (m, 6H, aromatic protons), 7.35 (d, J = 2.2 Hz, 1H, NH), 7.33 – 7.27 (m, 2H, aromatic protons), 7.21 (s, 1H, aromatic proton), 7.09 – 7.03 (m, 1H, aromatic proton), 6.96 (dd, J = 8.7, 2.2 Hz, 1H, CH), 4.11 (d, J = 3.5 Hz, 2H, CH₂), 3.22 (t, J = 7.2 Hz, 2H, CH₂), 3.15 – 3.05 (m, 2H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 155.30, 145.15, 139.77, 135.80, 133.45, 130.58, 130.08, 129.94, 129.71, 128.19, 125.59, 124.21, 119.78, 117.08, 112.73, 111.46, 110.82, 52.26, 40.22, 23.36. MS (ESI⁺) m/z calcd for C₂₄H₂₄N₃O₂ ⁺ [M+H]⁺ 386.2, found 386.2. Purity = 96.3%.

3j : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl dimethylcarbamate: white solid (92% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H, NH), 7.30 (d, J = 4.4 Hz, 4H, aromatic protons), 7.25 – 7.23 (m, 2H, aromatic protons), 7.22 (s, 1H, aromatic proton), 6.92 – 6.86 (m, 2H, aromatic protons), 3.82 (s, 2H, CH₂), 3.20 (s, 1H, CH), 3.14 (s, 3H, CH₃), 3.03 (s, 3H, CH₃), 2.91 (s, 4H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 155.75, 145.91, 136.03, 133.12, 130.66, 130.19, 129.98, 128.17, 125.97, 116.10, 112.91, 110.92, 110.79, 54.59, 52.24, 30.52, 23.24. MS (ESI⁺) m/z calcd for C₂₀H₂₄N₃O₂ ⁺ [M+H]⁺ 338.2, found 338.2. Purity = 95.3%.

3k : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl diethylcarbamate: white solid (90% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H, NH), 7.31 – 7.19 (m, 6H, aromatic protons), 7.15 (d, J = 8.7 Hz, 1H, aromatic proton), 6.87 (dd, J = 8.7, 2.3 Hz, 1H, aromatic proton), 6.79 (d, J = 1.8 Hz, 1H, CH), 3.78 (s, 2H, CH₂), 3.44 (m 4H, CH₂), 2.88 (s, 4H, CH₂), 1.26 (m, 6H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.40, 144.63, 139.58, 133.99, 128.35, 128.24, 127.56, 126.96, 123.37, 116.38, 113.35, 111.42, 110.94, 53.52, 49.01, 43.15, 42.17, 25.32, 14.22, 13.44. MS (ESI⁺) m/z calcd for C₂₂H₂₈N₃O₂ ⁺ [M+H]⁺ 366.2, found 366.2. Purity = 98.2%.

3l : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl dipropylcarbamate: white solid (87% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H, NH), 7.27 (d, J = 5.7 Hz, 4H, aromatic protons), 7.22 (m, J = 6.1, 1.4 Hz, 2H, aromatic protons), 7.14 (d, J = 8.7 Hz, 1H, aromatic proton), 6.85 (dd, J = 8.7, 2.3 Hz, 1H, aromatic proton), 6.79 (d, J = 1.9 Hz, 1H, CH), 3.77 (s, 2H, CH₂), 3.36 (t, J = 7.6 Hz, 2H, CH₂), 3.29 (t, J = 7.6 Hz, 2H, CH₂), 2.87 (s, 4H, CH₂), 1.67 (m, 4H, CH₂), 0.94 (m, 6H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.85, 144.71, 139.63, 133.97, 128.36, 128.23, 127.57, 126.96, 123.32, 116.40, 113.44, 111.39, 110.93, 53.55, 49.48, 49.16, 49.04, 25.35, 22.02, 21.27, 11.29. MS (ESI⁺) m/z calcd for C₂₄H₃₂N₃O₂ ⁺ [M+H]⁺ 394.2, found 394.2. Purity = 97.7%.

3m : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl dibutylcarbamate: white solid (91% yield). ¹H NMR (300 MHz, CDCl₃) δ 9.44 (s, 1H, NH), 7.52 – 7.39 (m, 2H, aromatic protons), 7.37 – 7.18 (m, 5H, aromatic protons), 7.08 (d, J = 2.2 Hz, 1H, aromatic proton), 6.76 (dd, J = 8.7, 2.2 Hz, 1H, aromatic proton), 6.49 (s, 1H, CH), 3.89 (s, 2H, CH₂), 3.39 (t, J = 7.5 Hz, 2H, CH₂), 3.28 (t, J = 7.5 Hz, 2H, CH₂), 2.95 – 2.80 (m, 2H, CH₂), 2.71 (t, J = 7.8 Hz, 2H, CH₂), 1.74 – 1.52 (m, 4H, CH₂), 1.36 (m, 4H, CH₂), 0.96 (m, 6H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ 156.05, 144.35, 133.86, 132.75, 129.68, 128.75, 128.61, 126.98, 124.26, 115.98, 111.92, 110.51, 110.11, 51.27, 47.46, 47.17, 46.92, 30.84, 30.12, 22.40, 20.01, 13.85. MS (ESI⁺) m/z calcd for C₂₆H₃₆N₃O₂ ⁺ [M+H]⁺ 422.3, found 422.3. Purity = 96.7%.

3n : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl diphenylcarbamate: white solid (93% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 1H, NH), 7.33 – 7.25 (m, 8H, aromatic protons), 7.22 (d, J = 2.3 Hz, 1H, aromatic proton), 7.20 – 7.10 (m, 7H, aromatic protons), 7.06 (d, J = 8.7 Hz, 1H, aromatic proton), 6.83 (dd, J = 8.7, 2.3 Hz, 1H, aromatic proton), 6.73 (d, J = 1.9 Hz, 1H, CH), 3.69 (s, 2H, CH₂), 2.81 (s, 4H, CH₂), 2.41 – 2.32 (m, 1H, NH). ¹³C NMR (101 MHz, CDCl₃) δ 154.22, 144.33, 142.46, 139.44, 134.07, 128.98, 128.37, 128.23, 127.48, 127.01, 126.30, 123.49, 115.99, 113.49, 111.43, 110.80, 53.50, 48.96, 25.31. MS (ESI⁺) m/z calcd for C₃₀H₂₈N₃O₂ ⁺ [M+H]⁺ 462.2, found 462.2. Purity = 95.6%.

3o : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl methoxy(methyl)carbamate: brown solid (85% yield). ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H, NH), 7.44 – 7.37 (m, 2H, aromatic protons), 7.32 – 7.21 (m, 4H, aromatic protons), 7.22 – 7.16 (m, 2H, aromatic protons), 6.84 (dd, J = 8.6, 2.2 Hz, 1H, aromatic proton), 6.69 (s, 1H, CH), 5.86 (s, 1H, NH), 3.88 (s, 2H, CH₂), 3.80 (s, 3H, CH₃), 3.28 (s, 3H, CH₃), 2.94 (t, J = 7.5 Hz, 2H, CH₂), 2.85 (t, J = 6.8 Hz, 2H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 156.40, 143.97, 134.12, 133.74, 129.47, 128.74, 128.42, 127.11, 124.36, 115.87, 111.95, 110.94, 110.59, 61.72, 51.76, 47.32, 35.61, 23.04. MS (ESI⁺) m/z calcd for C₂₀H₂₄N₃O₂ ⁺ [M+H]⁺ 462.2, found 462.2. Purity = 95.1%.

3p : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl methyl(phenyl)carbamate: white solid (90% yield). ¹H NMR (400 MHz, MeOD) δ 7.42 (d, J = 4.2 Hz, 3H, aromatic protons), 7.40 – 7.35 (m, 5H, aromatic protons), 7.33 (d, J = 8.7 Hz, 1H, aromatic proton), 7.28 (m, 2H, aromatic protons), 7.14 (s, 1H, aromatic proton), 6.88 (d, J = 8.7 Hz, 1H, CH), 3.98 (s, 2H, CH₂), 3.42 (s, 3H, CH₃), 3.10 (m, 2H, CH₂), 3.03 (t, J = 7.4 Hz, 2H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 156.79, 145.57, 144.26, 135.73, 134.52, 130.35, 129.98, 129.80, 129.71, 128.20, 127.62, 127.02, 125.47, 116.85, 112.66, 111.28, 111.24, 52.50, 48.91, 38.46, 23.71. MS (ESI⁺) m/z calcd for C₂₅H₂₆N₃O₂ ⁺ [M+H]⁺ 400.2, found 400.2. Purity = 96.9%.

3q : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl azetidine-1-carboxylate: brown solid (85% yield). ¹H NMR (300 MHz, CDCl₃) δ 9.23 (d, J = 11.6 Hz, 1H, NH), 7.62 (d, J = 23.6 Hz, 3H, aromatic protons), 7.34 (q, J = 3.1 Hz, 2H, aromatic protons), 7.31 – 7.28 (m, 1H, aromatic proton), 7.19 – 7.10 (m, 2H, aromatic protons), 6.82 (m, 1H, aromatic proton), 6.60 (d, J = 3.1 Hz, 1H, CH), 4.15 (d, J = 32.9 Hz, 4H, CH₂), 3.85 (d, J = 2.9 Hz, 2H, CH₂), 2.95 – 2.75 (m, 4H, CH₂), 2.31 (m, 2H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 155.63, 144.04, 134.05, 129.40, 128.69, 128.32, 127.08, 124.13, 116.11, 111.78, 110.86, 110.60, 51.45, 50.10, 49.19, 47.11, 22.92, 15.72. HRMS (ESI⁺) m/z calcd for C₂₁H₂₄N₃O₂ ⁺ [M+H]⁺ 350.1863, found 350.1860. Purity = 97.6%.

3r : 3-(2-(dibenzylamino)ethyl)-1H-indol-5-yl pyrrolidine-1-carboxylate: brown solid (88% yield). ¹H NMR (400 MHz, MeOD) δ 7.32 (d, J = 3.2 Hz, 4H, aromatic protons), 7.31 – 7.25 (m, 2H, aromatic protons), 7.23 (d, J = 2.2 Hz, 1H, aromatic proton), 7.12 (s, 1H, CH), 6.86 (dd, J = 8.7, 2.3 Hz, 1H, aromatic proton), 3.87 (s, 2H, CH₂), 3.62 (t, J = 6.6 Hz, 2H, CH₂), 3.45 (t, J = 6.6 Hz, 2H, CH₂), 2.99 (s, 4H, CH₂), 1.99 (m, 4H, CH₂). ¹³C NMR (101 MHz, MeOD) δ 154.94, 144.25, 137.20, 134.52, 128.47, 128.27, 127.37, 127.28, 123.78, 115.70, 111.59, 111.18, 110.29, 52.37, 48.47, 46.13, 46.07, 25.38, 24.56, 23.94. HRMS (ESI⁺) m/z calcd for C₂₂H₂₆N₃O₂ ⁺ [M+H]⁺ 364.2020, found 364.2025. Purity = 96.7%.

3s : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl piperidine-1-carboxylate: brown solid (87% yield). ¹H NMR (300 MHz, CDCl₃) δ 9.14 (s, 1H, NH), 7.41 (d, J = 7.2 Hz, 2H, aromatic protons), 7.29 (m, 3H, aromatic protons), 7.21 (dd, J = 8.8, 1.4 Hz, 1H, aromatic proton), 7.11 (d, J = 1.8 Hz, 1H, aromatic proton), 5.96 (s, 1H, CH), 3.87 (s, 2H, CH₂), 3.62 (s, 2H, CH₂), 3.51 – 3.39 (m, 2H, CH₂), 2.85 (t, J = 7.4 Hz, 2H, CH₂), 2.75 (d, J = 7.2 Hz, 2H, CH₂), 1.64 (s, 6H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 155.12, 144.46, 133.92, 129.46, 128.72, 128.34, 127.13, 124.07, 116.16, 111.85, 110.81, 110.69, 51.78, 47.42, 45.15, 25.53, 24.27, 22.94. MS (ESI⁺) m/z calcd for C₂₃H₂₈N₃O₂ ⁺ [M+H]⁺ 378.2, found 378.2. Purity = 95.2%.

3t : 3-(2-(benzylamino)ethyl)-1H-indol-5-yl azepane-1-carboxylate: white solid (93% yield). ¹H NMR (300 MHz, CDCl₃) δ 8.96 (s, 1H, NH), 7.41 – 7.34 (m, 2H, aromatic protons), 7.34 – 7.25 (m, 3H, aromatic protons), 7.21 (d, J = 8.7 Hz, 1H, aromatic proton), 7.15 (d, J = 2.2 Hz, 1H, aromatic proton), 6.82 (dd, J = 8.6, 2.2 Hz, 1H, aromatic proton), 6.65 (s, 1H, CH), 4.86 (s, 1H, NH), 3.84 (s, 2H, CH₂), 3.65 – 3.56 (m, 2H, CH₂), 3.49 (t, J = 6.0 Hz, 2H, CH₂), 2.82 (m, 4H, CH₂), 1.87 – 1.72 (m, 4H, CH₂), 1.72 – 1.53 (m, 4H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 155.97, 144.54, 135.58, 133.94, 129.12, 128.62, 127.97, 127.26, 123.89, 116.26, 111.72, 111.53, 110.77, 47.85, 47.35, 47.10, 28.65, 28.10, 27.46, 26.94, 23.59. MS (ESI⁺) m/z calcd for C₂₄H₃₀N₃O₂ ⁺ [M+H]⁺ 392.2, found 392.2. Purity = 97.4%.

3u: 3-(2-(benzylamino)ethyl)-1H-indol-5-yl morpholine-4-carboxylate: white solid (92% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H, NH), 7.44 – 7.36 (m, 2H, aromatic protons), 7.29 (t, J = 7.0 Hz, 2H, aromatic protons), 7.26 – 7.19 (m, 2H, aromatic protons), 7.17 (d, J = 2.3 Hz, 1H, aromatic proton), 6.82 (dd, J = 8.7, 2.2 Hz, 1H, aromatic proton), 6.66 (s, 1H, CH), 5.96 (s, 1H, NH), 3.86 (s, 2H, CH₂), 3.79 – 3.71 (m, 4H, CH₂), 3.68 (s, 2H, CH₂), 3.52 (s, 2H, CH₂), 2.91 (t, J = 6.9 Hz, 2H, CH₂), 2.83 (t, J = 6.9 Hz, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 155.00, 144.30, 134.62, 134.04, 129.30, 128.70, 128.23, 127.22, 124.09, 116.09, 111.82, 111.31, 110.72, 66.55, 52.02, 47.63, 44.80, 44.11, 23.32. MS (ESI⁺) m/z calcd for C₂₂H₂₆N₃O₃ ⁺ [M+H]⁺ 380.2, found 380.2. Purity = 97.4%.

4c: 3-(2-aminoethyl)-1H-indol-5-yl pentylcarbamate: white solid (90% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.82 (s, 1H, NH), 7.28 – 7.21 (m, 1H, aromatic proton), 7.12 (d, J = 8.7 Hz, 1H, aromatic proton), 6.88 – 6.78 (m, 2H, aromatic protons), 5.27 (t, J = 5.8 Hz, 1H, CH), 3.22 (q, J = 6.7 Hz, 2H, CH₂), 2.89 (t, J = 6.6 Hz, 2H, CH₂), 2.75 (t, J = 6.6 Hz, 2H, CH₂), 1.63 – 1.46 (m, 4H, CH₂), 1.36 – 1.24 (m, 4H, CH₂), 0.92 – 0.82 (m, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.95, 144.25, 134.21, 127.68, 123.65, 116.21, 113.34, 111.56, 110.96, 42.12, 41.31, 29.57, 29.18, 28.95, 22.36, 14.01. MS (ESI⁺) m/z calcd for C₁₆H₂₄N₃O₂ ⁺ [M+H]⁺ 290.2, found 290.2. Purity = 95.0%.

4d : 3-(2-aminoethyl)-1H-indol-5-yl hexylcarbamate: white solid (93% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H, NH), 7.27 – 7.20 (m, 1H, aromatic proton), 7.12 (d, J = 8.7 Hz, 1H, aromatic proton), 6.88 – 6.77 (m, 2H, aromatic protons), 5.25 (t, J = 5.9 Hz, 1H, CH), 3.21 (q, J = 6.7 Hz, 2H, CH₂), 2.89 (t, J = 6.6 Hz, 2H, CH₂), 2.75 (t, J = 6.6 Hz, 2H, CH₂), 1.53 (m, 8.4 Hz, 4H, CH₂), 1.34 – 1.19 (m, 6H, CH₂), 0.86 (t, J = 6.7 Hz, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 155.94, 144.26, 134.21, 127.69, 123.64, 116.22, 113.37, 111.56, 110.96, 42.12, 41.34, 31.48, 29.85, 29.20, 26.47, 22.58, 14.03. MS (ESI⁺) m/z calcd for C₁₇H₂₆N₃O₂ ⁺ [M+H]⁺ 304.2, found 304.2. Purity = 95.8%.

4e : 3-(2-aminoethyl)-1H-indol-5-yl heptylcarbamate: white solid (93% yield). ¹H NMR (400 MHz, MeOD) δ 7.33 (d, J = 8.7 Hz, 1H, aromatic proton), 7.27 (d, J = 2.3 Hz, 1H, aromatic proton), 7.16 (s, 1H, CH), 6.85 (dd, J = 8.7, 2.2 Hz, 1H, aromatic proton), 3.18 (t, J = 7.1 Hz, 2H, CH₂), 3.06 (t, J = 6.9 Hz, 2H, CH₂), 2.97 (t, J = 7.0 Hz, 2H, CH₂), 1.56 (q, J = 7.0 Hz, 2H, CH₂), 1.39 – 1.30 (m, 8H, CH₂), 0.95 – 0.89 (m, 3H, CH₃). ¹³C NMR (101 MHz, MeOD) δ 157.13, 144.28, 134.52, 127.19, 124.14, 115.78, 111.30, 110.53, 110.17, 40.66, 40.62, 31.58, 29.48, 28.74, 26.48, 25.18, 22.28, 13.03. MS (ESI⁺) m/z calcd for C₁₈H₂₈N₃O₂ ⁺ [M+H]⁺ 318.2, found 318.2. Purity = 95.5%.

The ChE inhibition activity of the synthesized CTDs was performed according to modified Ellman’s method. Donepezil and rivastigmine were used as reference standards. Butyrylcholinesterase (BuChE, E.C. 3.1.1.8, from equine serum), acetylcholinesterase (AChE, E.C. 3.1.1.7, Type V-S, lyophilized powder, from electric eel, 1000 unit), butyrylthiocholine iodide (BTCI), acetylthiocholine iodide (ATCI), and 5,5-dithiobis-(2-nitrobenzoic acid) (DTNB) were purchased from Sigma-Aldrich. The tested compounds were dissolved in DMSO (1%, analytical grade) and then diluted in phosphate buffer (75 mM, pH 7.4) to obtain the terminal concentrations required. At least ten concentration gradients were set for each compound in triplicate to detect the inhibition rate for BuChE, and five concentration gradients were set for each compound in triplicate to detect the inhibition rate for AChE. Specific experiment processes were conducted as in previous works (Zhang et al., 2022a). Specifically, 10 µl prepared AChE or BuChE solution (1.0 U/ml), 25 µl prepared tested compounds solution, and 65 µl phosphate buffer (pH 8.0, 0.1 mol/L) were mixed in each well of 96-well plates. Then, the 96-well plates were preincubated for 20 min at 37°C in a constant temperature incubator. The wells in the control group were operated under the same conditions without inhibitors, and the wells in the blank group were operated under the same conditions without enzyme solutions and inhibitors. Subsequently, 100 µl prepared DTNB solution (0.35 mM) and 50 µl prepared BTCI or ATCI solution (1.0 mM) were quickly added to each well, and the mixture reacted 5 min at room temperature. The OD values were tested at 412 nm using a microplate reader (Bio-Rad Laboratories, CA, United States). The IC₅₀ values were calculated using IBM SPSS Statistics 25.0 software. All experiments were performed in triplicate, and the results were shown as the mean ± SD.

In the kinetic study, the preincubated time of the mixture (BuChE, inhibitors solution, and phosphate buffer) were 2, 5, 10, 15, 20, 30, 40, 50, and 60 min, respectively. Other than that, the rest operation was the same as mentioned above. The obtained activities of BuChE were plotted against time and fitted to equation (A = A₀ • e^-kobst + A_∞) to determine rate constant k_obs by GraphPad Prism 8.0 software. Thereinto, A stands for the activity of BuChE at each time t, A₀ stands for the activity of BuChE at time t = 0, and A_∞ stands for the activity of BuChE at infinite time. Then, the created reciprocal k_obs ⁻¹ values needed to be plotted against the reciprocal concentration C⁻¹. According to the plot, k₃ is calculated from the Y-intercept, and k_c was calculated from the slope of the resulting linearization according to equation (k_obs ⁻¹ = k_c • k₃ ⁻¹ • C⁻¹ + k₃ ⁻¹) by GraphPad Prism 8.0 software.

Schrodinger software (Release 2019-2, Schrodinger, LLC, New York, NY, 2019) is used to conduct a molecular docking study. The structures of the hBuChE (PDB code: 4TPK) and hAChE (PDB code: 4M0F) are retrieved from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/). According to the previous method (Liu et al., 2022), the crystal structure profiles of BuChE and AChE are prepared by the Maestro Protein Preparation Wizard model by adding hydrogen atoms and straining minimization using the OPLS3 force field. And the ionization state is set at pH 7.0 ± 2.0. Then, the structures of the tested compounds are added to the hydrogen atoms at a neutralized environment, minimized by MMFFs forcefield, generating 3D coordinates. The binding sites of N-((1-(2,3-dihydro-1H-inden-2-yl) piperidin-3-yl) methyl)-N-(2-methoxyethyl)-2-naphthamide and territrem B in BuChE and AChE, respectively, are selected as the active sites for docking. The receptor grid is created at the selected residues using the grid box at the size of 20Å. Ultimately, molecular docking is run using the standard precision (SP). Other than above mentioned, the other docking parameters are set as default.

The cell lines present in this study were purchased from the China Center for Type Collection (CCTCC, China). For cytotoxicity assay, HT-22, BV2, SH-SY5Y, HepG2, and LO2 cells were incubated in 96-well plates at the density of 5 × 10³ per well. After incubation for 12 h at 37°C, the tested compounds with the required concentrations were added to the corresponding wells and continuously incubated for 24 h at 37°C. Then, the prepared MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) solution was added to each well and co-incubated for another 4 h at 37°C. Then, the supernatant was removed, and 100 μl DMSO was added to each well. The OD value of each well was detected at 570 nm using a microplate reader (Bio-Rad Laboratories, CA, United States). The IC₅₀ values were calculated using IBM SPSS Statistics 25.0 software. All experiments were performed in triplicate, and the results were shown as the mean ± SD.

For the neuroprotection assay, HT-22 cells were incubated in 96-well plates at the density of 5 × 10³ per well. After incubation for 12 h at 37°C, the tested compounds with required concentrations and H₂O₂ (500 μM) were added to the corresponding wells and continuously incubated for 24 h at 37°C. Then, the prepared MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) solution was added to each well and co-incubated for another 4 h at 37°C. Then, the supernatant was removed, and 100 μl DMSO was added to each well. The OD value of each well was detected at 570 nm using a microplate reader (Bio-Rad Laboratories, CA, United States). The cell viability values were calculated following the following equation: (OD₅₇₀ (tested compounds) –OD₅₇₀ (blank))/(OD₅₇₀ (control) – OD₅₇₀ (blank)) × 100%. All experiments were performed in triplicate, and the results were depicted as the mean ± SD.

Trolox was considered as standard, and its ORAC value was set as 1. Tested compounds in required concentrations (20 μl) and fluorescein solution (120 μl) were first co-incubated in a 96-well plate for 15 min at 37°C. Next, AAPH solution (60 µl) was added to each well. Then, the plate was immediately placed into a microplate reader, and the fluorescence of each well was detected every 2 min for 90 min with excitation at 485 nm and emission at 535 nm. After that, the fluorescence intensity was plotted on the vertical axis, and time was plotted on the horizontal axis. The antioxidant curves were normalized to the curve of the blank in the same assay. The AUC (area under the fluorescence decay curve) was obtained using GraphPad Prism 8.0 software. Net AUC = AUC_antioxidant – AUC_blank. Subsequently, the net AUC value was plotted on the vertical axis, and antioxidant concentration was plotted on the horizontal axis. ORAC value = slope_antioxidant/slope_Trolox. All experiments were conducted in triplicate, and the terminal ORAC values were depicted as the mean ± SD.

Inhibition assay on COX-2 was performed using a commercially available COX-2 screening assay kit (Beyotime, China, lot: S0168). At the initial screening, the tested concentrations of the selected compounds were 40, 20, 10, 5, and 2.5 μM. The reference concentrations (celecoxib) were 1.28, 0.64, 0.32, 0.16, and 0.08 μM. The specific experimental operations were conducted following the instruction of the assay kit. All experiments were conducted in triplicate, and the terminal inhibitory results were depicted as the mean ± SD.

All results were determined by ANOVA (analysis of variance) following Fisher’s PLSD procedure for post hoc comparison to verify the significance between the two means. p values less than 0.05 were considered statistically significant. The data were handled by SPSS 25.0 software.

The starting material 1 was synthesized from commercially available 5-methoxytryptamine via the process of amino protection and demethylation (Zhang et al., 2022a). Subsequently, the benzyl-protected tryptamine analog 1 was acylated under the condition of triphosgene and then reacted with diverse amines to give the CTDs 2a-2u. Then, selectively removing one or two benzyl groups by controlling the reaction conditions, the CTDs 3a-3u or 4c-4e were obtained, respectively (Scheme 2). The structures of these CTDs were characterized by HRMS and nuclear magnetic resonance (NMR). All of them were produced in mild-to-good yields (53%–95%). The purity of these products was detected by high-performance liquid chromatography (HPLC) analysis and reached more than 95%.

Ellman’s colorimetric assay was performed to evaluate the inhibitory activity of synthesized compounds on acetylcholinesterase (AChE) and BuChE, and donepezil and rivastigmine were selected as the reference ChE inhibitors (Hoffmann et al., 2019). The dibenzyl-substituted carbamylated compounds (2a-2u) were first selected to study the structure-activity relationships (SARs) of different carbamate moieties for ChE inhibition (Table 1; Figure 3). The results showed that most of these compounds had a poor inhibitory effect on AChE, except for N-methoxymethylamine (2o) and azetidine (2p) substituted compounds. However, all these compounds possessed good-to-excellent inhibition potency on BuChE. In detail, for the compounds bearing terminal secondary amine carbamate group were chain alkyl amine, compounds 2a-2e bearing three to seven carbon chains showed great inhibitory activity. Among them, the inhibition efficacy of 2a with three-carbon chain was slightly weaker than that of 2c-2e with longer carbon chains. When the terminal residues were ring carbon chains, the activity of ternary ring (2f) was significantly stronger than that of the six-membered ring (2h) and five-membered ring (2g). When the alkyl ring was replaced with a benzene ring, the activity of 2i was obviously decreased, indicating that the existence of π electrons for this scaffold probably had a negative influence on the inhibition potency of BuChE. In order to preliminarily verify this hypothesis, the molecular docking study was performed. The result showed that 2h could form a hydrogen bond interaction with Pro285 and Leu286, which was the key residue in the acyl-binding pocket of BuChE (PDB: 4TPK). Meanwhile, it could also form π–π stacking interactions with Tyr332 and Phe329, which were the residues in the peripheral anion site (PAS) (Figures 2A,B). Differently, 2i could only form π–π stacking interactions with Trp231 and Trp82, which were the key residues in the acyl-binding pocket and choline-binding pocket of BuChE, respectively. This observation indicated that the subtle difference might be the reason for the lower activity of 2i than 2h. Moreover, when the terminal residue was replaced with tertiary amine carbamate moieties, the different sizes and steric hindrance of substituents had different effects on the activity. For the ring-opening amino segment, dimethylamine (2j) and methoxymethylamine (2o) substituted compounds possessed great inhibition potency. Compounds with dipropylamine (2l), dibutylamine (2m), and N-methylaniline (2p) also exhibited favorable inhibition potency. However, the inhibition potency of compounds with diethylamine (2k) and diphenylamine (2n) was relatively weak. All these results showed that the inhibition potency on BuChE was not only regulated by the steric hindrance, but also adjusted by the size of the carbamate residue. When the carbamate residues were relatively rigid alkylamine fragments (2q-2t), the inhibition efficacy was decreased with the expanding ring. Among them, 2p with azetidine residue exhibited quite inhibitory activity against BuChE. Besides, when the cyclohexane was replaced with morpholine (2u), the inhibition efficacy was obviously decreased. According to the phenotypic result of the molecular docking study, the introduction of morpholine changed the lowest energy conformation of the compound, and the subtle variation weakened the affinity of the indole ring to the acyl-binding pocket and the whole compound to the active sites of BuChE (Figures 2C–F). As for the subtle changes in the study of SAR, further in-depth research is ongoing to clarify the observation.

By considering the influence of the benzyl group on the affinity of compounds to the enzyme, further SAR studies on 3a-3u with monobenzyl substituent and 4c-4e without benzyl group were evaluated, and the results are depicted in Table 2 and Figure 3. Overall, the reduction or elimination of benzyl groups decreased the BuChE inhibitory activity of the compounds. Noteworthily, most monobenzyl-substituted CTDs possessed mild-to-good inhibition efficacy on AChE, significantly different from dibenzyl-substituted carbamylated tryptamine derivatives.

For more details, the BuChE inhibitory activity of these compounds exhibited different SAR trends from the dibenzyl-substituted compounds, which might be due to the variation of the carrier scaffold. When the carbamate residue was the terminal secondary alkyl amine, the length of carbon chains or the size of ring carbon chains exhibited a slight influence on the inhibitory activity (3a-3h). Similar to the dibenzyl-substituted tryptamine derivatives, the replacement of cyclohexane with the benzene ring, the inhibitory activity of 3i obviously decreased. When the terminal residue was the ring-opening tertiary amine carbamate moiety, the trend of the inhibitory activity of 3j-3p against BuChE was significantly different from the results of 2j-2p. Combining the SARs results of dibenzyl-substituted tryptamine derivatives, the variation further suggested that the inhibition potency was regulated by both the carbamate moiety and the size of the carrier scaffold. When the terminal residue was replaced with the relatively rigid alkylamine fragments, the compound with azetidine residue (3q) exhibited significant inhibition potency on BuChE, and the morpholine substituted compound 3u exhibited weak inhibition potency, similar to the observed phenomenon in 2q and 2u. However, the inhibitory activity was increased with the expanding ring with five-to-seven members (3r-3t), inconsistent with the observed trend of disubstituted compounds.

Besides, according to the IC₅₀ values of the AChE inhibition assay, the length of the carbon chain of secondary amine in the carbamate group had a weak influence on AChE inhibition (3a-3e). When the unbranched alkyl group of 3a-3e was replaced with cycloalkyl (3f-3h), the resulting compounds suffered a 1.3–88-fold decrease in the AChE inhibitory activity. When aniline replaced cyclohexylamine, the inhibitory activity on AChE of 3i was markedly enhanced. The AChE inhibitory activity of different tertiary amine derivatives (3j-3n and 3p) was also investigated. Among them, compound 3i with a small bulky tertiary amine had the optimal potency on AChE. The methoxamine analog 3o displayed comparable activity against AChE to that of 3i. In addition, we explored the effect of different nitrogen-containing heterocycles (3q-3u) on the inhibitory activity against AChE. Interestingly, compound 3q bearing an azetidinyl group showed comparable AChE inhibitory activity to that of rivastigmine, providing valuable guidance for further research. The summary of the SARs study is depicted in Figure 4.

In addition, the CTDs 4c-4e without benzyl groups also possessed good inhibitory activity on BuChE (Table 2). The longer length of carbon chains had positive effects on the BuChE inhibition efficacy. However, the overall activity of the non-benzyl group was weaker than that of benzyl-substituted compounds. At the same time, considering the stability of this series of compounds, the study only evaluated the inhibition potency of 4c-4e, and the results further confirmed the importance of the benzyl group for the affinity of tryptamine derivatives to the enzyme.

A molecular docking study was performed to predict the binding mode of the synthesized CTDs to hBuChE (PDB code: 4TPK) and hAChE (PDB code: 4M0F) (Brus et al., 2014; Liu et al., 2022). Given that the majority of synthesized tryptamine derivatives have significant inhibition efficacy on BuChE, we conducted a preliminary investigation into the action mode of various series of compounds (Figure 5). Docking poses indole fragments in compounds with 3- and 4-carbon chains (2a and 2b, respectively) can form π–π stacking interactions and/or π–cation interactions with residues in the acyl-binding pocket (Trp231) and PAS (Phe329). Only stacking interactions with PAS (Tyr332, Phe329) or H-bond interactions with Ala328 can form the indole ring as increasing the alky carbon chain lengthens (2c-2e). The 2e-bearing 7-carbon chain can form two stacking interactions with benzyl benzene and Trp231, but the indole fragment cannot form any interactions with the acyl-binding pocket or PAS in its structure. Furthermore, one of the benzyls in 2a and 2d can interact with PAS via an π–π stacking interaction (Tyr332). The slight difference is that 2b and 3d can form π–π stacking interaction with the choline-binding site (Trp82). However, the benzyl group in 2c cannot form any interaction with active residues. Moreover, the tertiary amine nitrogen atom tends to form ions in the body and form H-bond interaction with part of the site cavity (Pro285), which can be observed in 2c, 2e, 2f, and 2q. By the way, due to the initial characteristic of the nitrogen atom, a similar phenomenon can also be observed in 3a-3d, 3f, and 3q. All these results indicate that the variation of chain length has a certain effect on the action mode of compounds with BuChE. Notably, when one benzyl group is eliminated, the action mode is also changed. In contrast to 2a, 3a’s benzyl benzene can form stacking interactions with an acyl-binding pocket (Trp231) and a PAS (Phe329) rather than an indole fragment. Differently, 3c bearing 5-carbon chain and 3d bearing 6-carbon chain can form H-bond with acyl-binding pocket (Leu286) and π–π stacking interaction with PAS (Phe329) in their indole fragments, and their benzyl group can also form π–π stacking interactions with PAS (Tyr332 and Phe329). In addition, 3b bearing 4-carbon chain and 3e bearing 7-carbon chain can only form interactions with PAS. Thereinto, 3e can also form H-bond with the key residue (His438) of the catalytic active site (CAS) and π–π stacking interactions with the choline-binding site (Trp82). When the terminal residue is a 3-carbon ring chain, the 2f bearing dibenzyl and 3f bearing monobenzyl groups all form π–π stacking interactions between the benzyl group and the acyl-binding pocket (Trp231) and PAS (Phe329), and the indole fragment with PAS (Tyr332). Furthermore, their indole fragment also can form π–π stacking interactions with the choline-binding site (Trp82). When the amino residue is relatively rigid alkyl amine, compounds bearing azetidine-based carbamate residue showed different modes of action. Among them, 2q with dibenzyl groups can form H-bond interactions with acyl-binding pockets (Leu286) and π–π stacking interactions with PAS (Phe329), and benzyl groups can also form π–π stacking interactions with PAS (Tyr332). 3q with a monobenzyl group, on the contrary, can only form π–π stacking interactions with acyl-binding pockets (Trp231) and PAS (Phe329) in its benzyl group. When the benzyl group is completely removed, 4e in its indole fragment can form stacking interactions with the choline-binding site (Trp82) and H-bond interactions with CAS (His328). At the same time, it can form π–cation interaction and H-bond interaction with PAS (Phe329 and Thr120, respectively). All these results of the predicted action mode further indicate that the inhibition efficacy of this kind of compounds on BuChE is modulated by both the carbamate residues and carrier scaffolds. The subtle difference may be the key reason for their different inhibition potency because their different conformations have been varied.

In view of 2q and 3q bearing azetidine-based carbamate residue possessing better inhibition efficacy on AChE than other synthesized compounds, the action modes of 2q and 3q with AChE are preliminarily predicted by molecular docking (Figure 6). Docking poses of 2q and 3q with hAChE (PDB code: 4M0F) reveal that the compounds can form π–π stacking interactions with PAS (Trp86, Tyr341) in their benzyl group and indole fragment, as well as cation interactions with PAS (Tyr337) in their tertiary or secondary amine. Because the number of the containing benzyl group is different, one of the benzyl groups in 2q can also form π–π stacking interaction with CAS (His447). However, the obtained IC₅₀ value of 2q is larger than that of 3q. Given that the distances of π–π stacking interactions between compounds and PAS differ, we assume that more benzyl groups reduce the affinity of 2q to AChE, and research into the specific action mode of compounds on AChE is ongoing.

According to previous studies, compounds with larger molecular shapes are preferred to bind to BuChE because of the larger size of the BuChE binding pocket compared to AChE (Sawatzky et al., 2016). In view of the curiosity about the selective BuChE inhibitory activity of the series of bisbenzyl-substituted CTDs, we explored the possible mode of action of 2e and 2f for AChE and BuChE (Figure 7). As expected, the bisbenzyl-substituted CTDs 2e and 2f cannot completely bind to the AChE binding pocket. Thereinto, the benzyl groups of 2e and the carbamate residue of 2f are distributed outside the active pocket due to the relatively small binding pocket of AChE and the relatively large molecular scaffold. Differently, due to the relatively large binding pocket of BuChE, the whole skeletons of 2e and 2f exhibit favorable affinity with BuChE active sites, which explains the possible mechanism of the selectivity obtained in the enzyme inhibition assay.

Convincing evidence has demonstrated that carbamylated derivatives with ChE inhibition efficacy exhibit a pseudo-irreversible inhibition mode (Figure 8A) (Hoffmann et al., 2019; Zhang et al., 2022b). Enlightened by this, we further conducted a kinetic study to explore the inhibition type of the synthesized CTDs, which possessed excellent inhibitory activity on BuChE. According to the results of the equilibrium constant (k_c) for reversible combinations (Figure 8B), the carrier skeleton has a pronounced influence on the affinity between compounds and BuChE. Overall, compounds with monobenzyl substituents exhibit larger k_c values than those with dibenzyl groups, suggesting that the expansion of the carrier skeleton structure can decrease the affinity of compounds for BuChE. Combining the predicted action mode of these compounds with BuChE by molecular docking, the tryptamine skeleton is a key fragment that binds effectively to the enzyme. Besides, among the compounds with dibenzyl groups and compounds without benzyl group, the alkyl carbon chains in carbamate residues exhibit subtle influence for the affinity of compounds with enzyme, except for 2c bearing a 5-carbon chain, which possesses stronger affinity than others in this series of compounds. Particularly, 3c with the monobenzyl group shows a stronger affinity than that of rivastigmine. Furthermore, 3f bearing 3-ring alkyl carbon chain and 3s bearing piperidine-based carbamate residue have high affinity for BuChE. In addition, the results of the carbamylation rate constant (k₃, Figure 8C) showed that the increasing carbon chain has a negative effect on carbamate transfer from the carrier scaffold to the enzyme in dibenzyl-substituted compounds 2b-2e. However, there is no obvious effect of the carbamate residues in monobenzyl-substituted compounds 3c-3e on k₃. Compared with 2e and 3e, the benzyl-free compound 4e bearing a 7-carbon side chain shows a significantly larger carbamate transfer rate, suggesting that the carrier scaffold and side residue of carbamate moiety synergistically determined the carbamoylation rate. Besides, the cyclopropanamine residues of carbamate moiety have a positive effect on the carbamoylation rate (2f and 3f). Noteworthily, most of the tested compounds performed better affinity to BuChE and better carbamoylation efficacy because the k₃/k_c value of compounds was greater than that of rivastigmine (Figure 8D). Therefore, this series of compounds is worthy of further study to perform structure optimization and excavate novel tryptamine-based MTDLs.

In order to explore the applicability of the synthesized CTDs in neurological diseases, the neuronal cytotoxicity of the synthesized compounds was evaluated on mouse hippocampal neuronal cell line HT-22. Table 3 shows that the neuronal cytotoxicity of compounds (2a-2u) bearing dibenzyl groups on HT-22 is lower than that of compounds (3a-3u) bearing monobenzyl group in general. The cytotoxicity of benzyl-free compounds (4c-4e) exhibited a large difference that the 4c bearing 5-carbon alky chain residue showed little toxicity, but 4d and 4e bearing increasing carbon alkyl chain residues showed certain toxicity. In view of these CTDs endowed strong inhibition efficacy on BuChE, we preliminarily evaluated their safety range by comparing their IC₅₀ values on cytotoxicity and BuChE inhibitory activity. The results showed that most of the tested compounds possessed considerable safety range, and only a few compounds (3m and 3n) showed obvious toxicity. Therefore, the series of compounds with dibenzyl groups, especially compounds bearing ring carbon alkyl chains (2f-2h) and tertiary amine residues (2j-2u) with little cytotoxicity on HT-22, can be considered as potential lead building blocks for further structure optimization to develop novel effective agents against neurological diseases.

In order to further evaluate the applicability of the compounds with dibenzyl groups for neurological diseases, we also tested the cytotoxicity of the selected compounds (2f, 2h, 2j, 2m, 2o-2r, 2t, and 2u) bearing little toxicity on HT-22 cells, microglia cell line BV2, and human neuroblastoma cell line SH-SY5Y, which are widely used in the study of neurological diseases. Table 4 shows that all these tested compounds exhibited little or no toxicity on BV2 and SH-SY5Y cells, except for 2f and 2q, which exhibited certain toxicity. In view of some carbamate-based ChE inhibitors reported to be hepatotoxic, we further performed the preliminary evaluation of the hepatotoxicity of the selected compounds on human normal liver cell line LO2 and human hepatocellular carcinoma cell line HepG2. The results showed that all the tested compounds exhibited no hepatoxicity, suggesting that these CTDs can be safely used in drug discovery for further study.

Neuronal damage caused by oxidative stress has been widely recognized in various neurological diseases. It is of great significance to protect neurons damaged by oxidative stress for the treatment of neurological diseases (Bai et al., 2022; Wakhloo et al., 2022). To date, many tryptamine derivatives have been reported to endow favorable neuronal protective functions (Hanikoglu et al., 2020; Forman and Zhang, 2021). Given this, we performed an elementary evaluation of neuronal protection against neuronal death elicited by H₂O₂ of the selected CTDs, which possessed little neuronal toxicity. Figure 9 shows that most of the tested compounds exhibited certain neuronal protection efficacy compared with the model group, in which the cell viability of the model group significantly decreased to 61.07% after treatment with H₂O₂ (500 μM). Among them, 2g, 2h, 2j, 2m, 2o, and 2p showed relatively favorable neuroprotective effects (the cell viability was more than 70% at 5 and 10 μM), so further structure optimization based on these compounds is of great value for the development of neuronal protective agents. By the way, the compounds bearing azetidine-based carbamate residues (2q and 3q) exhibited no protective effects on H₂O₂-induced neuronal death. However, considering their extraordinary inhibitory activity on AChE and BuChE, this kind of compounds could be considered for drug development in peripheral cholinergic-related disease, which is ongoing in our current study.

Antioxidative effects are crucial in the treatment of many diseases (Ansari et al., 2020; Dumanovic et al., 2021). The Oxygen Radical Absorbance Capacity-Fluorescein (ORAC-FL) assay was used to preliminarily evaluate the antioxidant activities of the selected compounds (2g, 2h, 2j, 2m, 2o, and 2p), which endowed favorable BuChE inhibition efficacy, little neuronal toxicity, and neuroprotective effects. The vitamin E analog Trolox was used as a standard, and its ORAC value was set as 1. Melatonin was used as a positive control with an ORAC value equal to 2.5⁵¹. At the same time, the non-carbamoylated compound 1 of the tested CTDs was also evaluated as a reference. As shown in Figure 10, non-carbamoylated compound 1 was endowed with favorable oxygen radical scavenging property with a Trolox equivalent value equal to 3.92. However, the carbamylated derivatives showed decreasing antioxidant activities, suggesting that the hydroxyl group played an important role in radical scavenging. Among them, 2o bearing N-methoxymethylamine-based carbamate moiety exhibited a good antioxidant activity with Trolox equivalents value equal to 2.11, indicating that the special characteristic of methyl-methoxylamine fragment played certain modulation for the antioxidant activity. Besides, we also detected the inhibition efficacy of these compounds on NO production using the Griess reagent method. However, the results showed that most of this series of compounds had a weak inhibitory activity or even no effect, indicating that this series of compounds were insensitive to nitrogen radical.

Glia cells play a significant role in neurological diseases (Zhang et al., 2021; Cai et al., 2022; Rauf et al., 2022). Microglia can release large amounts of COX-2 after being stimulated by inflammatory substances. Similarly, the expression of COX-1 in astrocytes was largely unchanged after stimulation, but the expression of COX-2 was significantly increased (Fan et al., 2021; Ghazanfari et al., 2021; Iwata et al., 2021; Nagano et al., 2021; Kuo et al., 2022). Therefore, inhibition of COX-2 expression in glia cells is of great value in the treatment of neurological diseases. The COX-2 inhibitory activity of the selected compounds was preliminarily evaluated using a commercial assay kit. As shown in Figure 11, 2g and 2h bearing cyclopentanamine-based carbamate residue and cyclohexanamine-based carbamate residue, respectively, had good COX-2 inhibition efficacy compared with the non-carbamylated compound 1. However, other compounds bearing tertiary amine-based carbamate residues (2j, 2m, 2o, and 2p) showed mild-to-weak inhibition efficacy on COX-2. By analyzing the structures of the tested compounds, we assumed that hydrogen bond interaction plays a certain role in the inhibitory activity of COX-2.

According to the drug discovery, “the rule of 5” predicts that the poor druggability of the compound is more likely to appear when the molecular weight (MWT) is greater than 500, calculated Log P (MLog P) is greater than 4.15, H-bond acceptors are greater than 10, H-bond donors are greater than 5, and the number of rotatable bonds is greater than 10 (Lipinski et al., 2022). Given this, the predicted druggability of synthesized compounds was calculated by the SwissADME. Table 5 shows that the MWT values of all the synthesized compounds were less than 500, except for 2m and 2n. The number of H-bond acceptors and H-bond donors of all these compounds was in accordance with Lipinski’s rule. Most compounds possessed favorable MLog P and BBB permeation properties. All these predicted results provide guidance for further study and suggest the potential value of the tryptamine derivatives.

The spectral data and additional experimental information, except for those stated above, are presented in the Supplementary Material.